{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:49:10Z","timestamp":1782485350785,"version":"3.54.5"},"reference-count":49,"publisher":"Media Sphere Publishing House","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["S.S. Korsakov J. Neuro. Psych."],"published-print":{"date-parts":[[2026,6,26]]},"abstract":"<jats:p>Anxiety disorders represent the most prevalent category of mental health issues, particularly affecting individuals with chronic somatic conditions. Choosing an appropriate treatment can be challenging due to the frequent side effects associated with many anxiolytics and antidepressants, as well as the risk of drug-drug interactions, which is especially pertinent for patients with comorbidities. Afobazol was developed as a safer alternative to traditional benzodiazepine tranquilizers. Its active ingredient, fabomotizole, is a selective anxiolytic that operates through a unique mechanism designed to restore the structure and function of damaged nerve cells. The effectiveness and safety of fabomotizole have been investigated in clinical trials involving various anxiety disorders, including those associated with somatic pathology. Randomized clinical trials focused on patients with generalized anxiety disorder and adjustment disorder have demonstrated a significant anxiolytic effect of fabomotizole, comparable to that of benzodiazepines and significantly more effective than a placebo. Further studies confirmed its benefits in stabilizing autonomic functions, delivering antidepressant effects, and enhancing overall activity (antiasthenic effects). A review of clinical studies involving patients with comorbid conditions revealed fabomotizole\u2019s efficacy and good tolerability, with no significant drug-drug interactions, and a favorable impact on the management and prognosis of these conditions. The extended-release formulation of fabomotizole (AFOBAZOL RETARD) enhances patient compliance, thereby ensuring effective treatment for anxiety disorders and related conditions.<\/jats:p>","DOI":"10.17116\/jnevro202612606129","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:15:23Z","timestamp":1782483323000},"page":"29","source":"Crossref","is-referenced-by-count":0,"title":["The potential of a selective anxiolytic afobazole in clinical practice"],"prefix":"10.17116","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3872-5923","authenticated-orcid":false,"given":"O.S.","family":"Levin","sequence":"first","affiliation":[{"name":"Russian Medical Academy of Continuous Professional Education","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6743","reference":[{"key":"key-10.17116\/jnevro202612606129-1","unstructured":"2021 Global Burden of Disease (GBD) [online database]. Seattle: Institute for Health Metrics and Evaluation; 2024. Accessed 13 August 2025.  https:\/\/vizhub.healthdata.org\/gbd-results"},{"key":"key-10.17116\/jnevro202612606129-2","doi-asserted-by":"publisher","DOI":"10.1002\/da.22711"},{"key":"key-10.17116\/jnevro202612606129-3","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-023-05481-6"},{"key":"key-10.17116\/jnevro202612606129-4","doi-asserted-by":"publisher","DOI":"10.15829\/1728-8800-2022-3280"},{"key":"key-10.17116\/jnevro202612606129-5","doi-asserted-by":"publisher","DOI":"10.17116\/terarkh2017898104-109"},{"key":"key-10.17116\/jnevro202612606129-6","unstructured":"Ibatov AD. Effect of anxiety disorders on the course of coronary heart disease. Russkij Medicinskij Zhurnal. 2007;15(20):1443-1448. (In Russ.)"},{"key":"key-10.17116\/jnevro202612606129-7","doi-asserted-by":"publisher","DOI":"10.18087\/cardio.2018.9.10171"},{"key":"key-10.17116\/jnevro202612606129-8","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3999(99)00091-4"},{"key":"key-10.17116\/jnevro202612606129-9","unstructured":"Kopylov FYu, Syrkin AL, Drobizhev MYu, et al. Clinical and psychosomatic features of the course of hypertension in conditions of chronic stress. Klinicheskaya Meditsina. 2008;2:23-25. (In Russ.)"},{"key":"key-10.17116\/jnevro202612606129-10","unstructured":"Kalinina SY, Gulina NI, Belova AN, et al. Impact of anxiolytic Afobazol on treatment efficiency of essential hypertension with elderly women. Obozrenie Psikhiatrii i Meditsinskoy Psikhologii Imeni Bekhtereva. 2009;4:37-41. (In Russ.)"},{"key":"key-10.17116\/jnevro202612606129-11","doi-asserted-by":"publisher","DOI":"10.15829\/1560-4071-2023-5452"},{"key":"key-10.17116\/jnevro202612606129-12","unstructured":"Starostina YeG. Generalized anxiety disorder and symptoms of anxiety in general medical practice. Russkij Medicinskij Zhurnal. 2004;22:1277-1283. (In Russ.)"},{"key":"key-10.17116\/jnevro202612606129-13","unstructured":"Markyn SP. Anxiety disorders in back pain. Spravochnik Poliklinicheskogo Vracha. 2011;6:9-13. (In Russ.)"},{"key":"key-10.17116\/jnevro202612606129-14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.0268"},{"key":"key-10.17116\/jnevro202612606129-15","doi-asserted-by":"publisher","DOI":"10.46393\/27129675_2025_1_12-21"},{"key":"key-10.17116\/jnevro202612606129-16","doi-asserted-by":"publisher","DOI":"10.51793\/OS.2021.15.98.005"},{"key":"key-10.17116\/jnevro202612606129-17","unstructured":"Butko DY, Strelnikov AA, Kotelnikova TL, et al. About clinical use of sertraline and afobazol in patients with comorbidis depression and anxiety in postinsult period. Psikhofarmakologiya i Biologicheskaya Narkologiya. 2007;7(1):1464-1470. (In Russ.)"},{"key":"key-10.17116\/jnevro202612606129-18","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro2024124121126"},{"key":"key-10.17116\/jnevro202612606129-19","doi-asserted-by":"publisher","DOI":"10.2471\/B09333"},{"key":"key-10.17116\/jnevro202612606129-20","unstructured":"Razumnaja FG, Kamilov FH, Kapuler OM, et al. To pharmacology of Afobazole. Fundamentalnye Issledovaniya. 2014;7(4):848-855. (In Russ.)"},{"key":"key-10.17116\/jnevro202612606129-21","unstructured":"WHO Drug Information. 2012; 26:1, International Nonproprietary Names for Pharmaceutical Substances (INN). Accessed May 25, 2026.  https:\/\/cdn.who.int\/media\/docs\/default-source\/international-nonproprietary-names-(inn)\/rl67.pdf"},{"key":"key-10.17116\/jnevro202612606129-22","unstructured":"WHO Drug Information. 2014;28:4. Accessed May 25, 2026.  https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/272585ce-4010-47e9-bb9b-acd8c727ac30\/content"},{"key":"key-10.17116\/jnevro202612606129-23","unstructured":"Seredenin SB, Voronin MV. Neuroreceptor mechanisms involved in the action of afobazole. Eksperimentalnaya i Klinicheskaya Farmakologiya. 2009;72(1):3-11. (In Russ.)"},{"key":"key-10.17116\/jnevro202612606129-24","doi-asserted-by":"publisher","DOI":"10.24411\/2587-7836-2018-10017"},{"key":"key-10.17116\/jnevro202612606129-25","doi-asserted-by":"publisher","DOI":"10.1134\/S1027813319010187"},{"key":"key-10.17116\/jnevro202612606129-26","unstructured":"Bekker RA, Bykov YuV. Afobazole (fabomotizole): is it only an anxiolytic? An Israeli-Russian view of the problem. Psychiatriya i Psikhofarmakoterapiya. 2017;19(4):12-21. (In Russ.)"},{"key":"key-10.17116\/jnevro202612606129-27","unstructured":"Yastrebov DV, Mikhailova OI, Kostycheva EA. Afobazol administration in patients with sleep disorders comorbid with anxiety disorders. Psychiatriya i Psikhofarmakoterapiya. 2013;15(5):29-32. (In Russ.)"},{"key":"key-10.17116\/jnevro202612606129-28","doi-asserted-by":"publisher","DOI":"10.17116\/terarkh201688873-86"},{"key":"key-10.17116\/jnevro202612606129-29","unstructured":"Andriushchenko AV, Romanov DV, Smulevich AB. Psychopharmacotherapy of borderline anxiety disorders (comparative study of the anxiolytic effect of Afobazole and oxazepam in patients with adjustment disorders and generalized anxiety disorder). Russkij Medicinskij Zhurnal. 2006;14(9):725-730. (In Russ.)"},{"key":"key-10.17116\/jnevro202612606129-30","unstructured":"Syunyakov TS, Dorofeeva OA, Seredenin SB. Comparative study results therapeutic equivalence fabomotizole in dosage form with immediate and delayed release. Psychiatriya i Psikhofarmakoterapiya. 2021;1:4-10. (In Russ.)"},{"key":"key-10.17116\/jnevro202612606129-31","unstructured":"Syunyakov SA, Chumakov DV, Bochkaryov VK, et al. Effects of anxiolytic afobazol in patients with different personality. Sotsialnaya i Klinicheskaya Psikhiatriya. 2006;16(1):38-45. (In Russ.)"},{"key":"key-10.17116\/jnevro202612606129-32","unstructured":"Syunyakov TS, Syunyakov SA, Neznamov GG. Afobazole therapeutic niche: the reasoning. Psychiatriya i Psikhofarmakoterapiya. 2015;17(3):39-48. (In Russ.)"},{"key":"key-10.17116\/jnevro202612606129-33","unstructured":"Dorofeeva OA, Metlina MV, Siuniakov SA, et al. The effect of anxiolytic drug afobazole on the quality of life of patients with anxiety disorders. Kachestvennaya Klinicheskaya Praktika. 2016;(2):57-63. (In Russ.)"},{"key":"key-10.17116\/jnevro202612606129-34","unstructured":"Babyuk IA, Shults OE. Afobazol effectiveness research for the treatment of patients with generalized anxiety disorder. Psychiatriya i Psikhofarmakoterapiya. 2014;16(3):58-61. (In Russ.)"},{"key":"key-10.17116\/jnevro202612606129-35","unstructured":"Chakhava VO, Borukayev RR. Efficacy of Afobazole in generalized anxiety disorder in long-term therapy. Meditsinskie Novosti. 2011;1:50-53. (In Russ.)"},{"key":"key-10.17116\/jnevro202612606129-36","doi-asserted-by":"publisher","DOI":"10.21265\/PSYPH.2018.45.13934"},{"key":"key-10.17116\/jnevro202612606129-37","doi-asserted-by":"publisher","DOI":"10.48612\/psyph\/81zr-ax3e-ttvr"},{"key":"key-10.17116\/jnevro202612606129-38","unstructured":"Akarachkova YeS, Shvarkov SB, Mamiy VI. Afobazole in the treatment of vegetative manifestations of anxiety and maladaptation in patients with neurological and general somatic practice. Russkij Medicinskij Zhurnal. 2007;15(2):100-106. (In Russ.)"},{"key":"key-10.17116\/jnevro202612606129-39","unstructured":"Melnik MG, Kanorsky SG, Bogochanova OA, et al. Evaluation of short-term effects Afobazol in geriatric patients with combined psychosomatic diseases. Psychiatriya i Psikhofarmakoterapiya. 2014;16(4):46-51. (In Russ.)"},{"key":"key-10.17116\/jnevro202612606129-40","doi-asserted-by":"publisher","DOI":"10.18087\/cardio.2019.9.n468"},{"key":"key-10.17116\/jnevro202612606129-41","unstructured":"Medvedev VE. Treatment of anxiety-depressive disorders in medical division patients. Psychiatriya i Psikhofarmakoterapiya. 2015;1:22-30. (In Russ.)"},{"key":"key-10.17116\/jnevro202612606129-42","doi-asserted-by":"publisher","DOI":"10.15829\/1560-4071-2014-2-89-95"},{"key":"key-10.17116\/jnevro202612606129-43","unstructured":"Svishchenko EP. Experience of using the drug Afobazole in patients with hypertension and panic attacks. Vnutrennyaya Meditsina. 2008;4(10). (In Russ.)"},{"key":"key-10.17116\/jnevro202612606129-44","unstructured":"Davydov AT, Litvintsev SV, Butko DY, et al. Experience in diagnosis and treatment of anxiety disorder in the poststroke period in patients after ischemic stroke. Russkij Medicinskij Zhurnal. 2008;16(5):266-270. (In Russ.)"},{"key":"key-10.17116\/jnevro202612606129-45","unstructured":"Vorobyova OV, Repina VV, Fateeva VV. An observational open study of the efficacy and safety of drug therapy with Afobazol in affective disorders patients with chronic cerebral ischemia. Psychiatriya i Psikhofarmakoterapiya. 2015;17(2):23-27. (In Russ.)"},{"key":"key-10.17116\/jnevro202612606129-46","unstructured":"Sholomov II, Lutoshkina EB, Salina EA. Efficacy of aphobazole in the treatment of anxiety disorders in patients with chronic cerebro-vascular insufficiency. S.S. Korsakov Journal of Neurology and Psychiatry. 2008;108(6):75-77. (In Russ.)"},{"key":"key-10.17116\/jnevro202612606129-47","unstructured":"Teterin DA. Use of Afobazole in the treatment of local hyperkineses. Vrach. 2011;9:54-58. (In Russ.)"},{"key":"key-10.17116\/jnevro202612606129-48","unstructured":"Akarachkova ES. Afobazole: new possibilities for the treatment of vegetative manifestations of anxiety in patients with neurological and general somatic practices. Pharmateka. 2006;13(128):25-27. (In Russ.)"},{"key":"key-10.17116\/jnevro202612606129-49","unstructured":"Dorozhenok IYu. Psychosomatic disorders: clinical and therapeutic aspects. Vrach. 2011;9:14-19. (In Russ.)"}],"container-title":["S.S. Korsakov Journal of Neurology and Psychiatry"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:16:38Z","timestamp":1782483398000},"score":1,"resource":{"primary":{"URL":"https:\/\/mediasphera.ru\/issues\/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova\/2026\/6\/1199772982026061029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,26]]}},"alternative-id":["10.17116\/jnevro202612606129"],"URL":"https:\/\/doi.org\/10.17116\/jnevro202612606129","relation":{},"ISSN":["1997-7298"],"issn-type":[{"value":"1997-7298","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,26]]}}}